Cargando…

Epigenetic Priming of AML Blasts for All-trans Retinoic Acid-Induced Differentiation by the HDAC Class-I Selective Inhibitor Entinostat

All-trans retinoic acid (ATRA) has only limited single agent activity in AML without the PML-RARα fusion (non-M3 AML). In search of a sensitizing strategy to overcome this relative ATRA resistance, we investigated the potency of the HDAC class-I selective inhibitor entinostat in AML cell lines Kasum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blagitko-Dorfs, Nadja, Jiang, Yi, Duque-Afonso, Jesús, Hiller, Jan, Yalcin, Arzu, Greve, Gabriele, Abdelkarim, Mahmoud, Hackanson, Björn, Lübbert, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3792939/ https://www.ncbi.nlm.nih.gov/pubmed/24116031 http://dx.doi.org/10.1371/journal.pone.0075258

Ejemplares similares

In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts
por: Greve, Gabriele, et al.
Publicado: (2023)

Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients
por: Stomper, Julia, et al.
Publicado: (2021)

Correction to: Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients
por: Stomper, Julia, et al.
Publicado: (2021)

The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation
por: Meier, Ruth, et al.
Publicado: (2022)

Quantitative determination of decitabine incorporation into DNA and its effect on mutation rates in human cancer cells
por: Öz, Simin, et al.
Publicado: (2014)

Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy
por: Srivastava, Pragya, et al.
Publicado: (2016)

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
por: Wagner, Julia M., et al.
Publicado: (2010)

AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms
por: Rejeski, Kai, et al.
Publicado: (2021)

Potential for subsets of wt-NPM1 primary AML blasts to respond to retinoic acid treatment
por: Bunaciu, Rodica P., et al.
Publicado: (2017)

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
por: Valinciute, Gintvile, et al.
Publicado: (2023)

Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours
por: Pili, R, et al.
Publicado: (2012)

Revisiting entinostat as an immune-potentiating adjuvant
por: McCaw, Tyler R., et al.
Publicado: (2018)

Preclinical rationale for entinostat in embryonal rhabdomyosarcoma
por: Bharathy, Narendra, et al.
Publicado: (2019)

Biomodulatory Treatment With Azacitidine, All-trans Retinoic Acid and Pioglitazone Induces Differentiation of Primary AML Blasts Into Neutrophil Like Cells Capable of ROS Production and Phagocytosis
por: Klobuch, Sebastian, et al.
Publicado: (2018)

Immunomodulation of HDAC Inhibitor Entinostat Potentiates the Anticancer Effects of Radiation and PD-1 Blockade in the Murine Lewis Lung Carcinoma Model
por: Kim, Yeeun, et al.
Publicado: (2022)

Targeting SALL4 by entinostat in lung cancer
por: Yong, Kol Jia, et al.
Publicado: (2016)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

All-trans-retinoic-acid and arsenic trioxide induced remission in promyelocytic blast crisis
por: Colvin, Teresa A., et al.
Publicado: (2018)

Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
por: Javorniczky, Nora Rebeka, et al.
Publicado: (2023)

DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy
por: Grishina, Olga, et al.
Publicado: (2015)

Treatment of Low-Blast Count AML using Hypomethylating Agents
por: De Bellis, Eleonora, et al.
Publicado: (2017)

Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
por: Karasic, Thomas B, et al.
Publicado: (2022)

Repeat to gene expression ratios in leukemic blast cells can stratify risk prediction in acute myeloid leukemia
por: Onishi-Seebacher, M., et al.
Publicado: (2021)

HDAC Inhibition to Prime Immune Checkpoint Inhibitors
por: Borcoman, Edith, et al.
Publicado: (2021)

Blast vacuolization in AML patients indicates adverse-risk AML and is associated with impaired survival after intensive induction chemotherapy
por: Ballo, Olivier, et al.
Publicado: (2019)

Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure
por: Freundt, Johanna K., et al.
Publicado: (2019)

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
por: Ny, Lars, et al.
Publicado: (2021)

The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells
por: Greve, Gabriele, et al.
Publicado: (2015)

All-trans retinoic acid synergizes with topotecan to suppress AML cells via promoting RARα-mediated DNA damage
por: Xu, Zhifei, et al.
Publicado: (2016)

Clinical Results of Hypomethylating Agents in AML Treatment
por: Cruijsen, Marjan, et al.
Publicado: (2014)

Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML
por: Sargent, J M, et al.
Publicado: (2001)

Expression of CD200 on AML blasts directly suppresses memory T-cell function
por: Coles, S J, et al.
Publicado: (2012)

High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity
por: Xu, Liangjing, et al.
Publicado: (2017)

Entinostat reverses P-glycoprotein activation in snail-overexpressing adenocarcinoma HCC827 cells
por: Tomono, Takumi, et al.
Publicado: (2018)

Low Autophagy (ATG) Gene Expression Is Associated with an Immature AML Blast Cell Phenotype and Can Be Restored during AML Differentiation Therapy
por: Jin, Jing, et al.
Publicado: (2018)

The role of VDR and BIM in potentiation of cytarabine–induced cell death in human AML blasts
por: Harrison, Jonathan S., et al.
Publicado: (2016)

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal
por: Estey, Elihu, et al.
Publicado: (2022)

Chemotherapy Promotes Release of Exosomes Which Upregulate Cholesterol Synthesis and Chemoresistance in AML Blasts
por: Hong, Chang-Sook, et al.
Publicado: (2021)

Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients
por: Holicek, Peter, et al.
Publicado: (2023)

Regulation of retinoic acid synthetic enzymes by WT1 and HDAC inhibitors in 293 cells
por: Li, Yifan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_j6hjhpvfvgo08u6fgb337vch1m